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Background. Phenylalanine is converted to para- and ortho-
tyrosine by hydroxyl free radical, or to para-tyrosine by the
phenylalanine hydroxylase enzyme. The aim of this study was
to measure para- and ortho-tyrosine in the urine and plasma
of patients with chronic renal disease and/or diabetes, to ob-
tain information on the renal handling of the different tyrosine
isomers and, furthermore, to measure urinary levels of 8-epi-
prostaglandin-F2a , a marker of lipid peroxidation.
Methods. In our cross-sectional study we measured para-,
ortho-tyrosine, and phenylalanine levels, using high perfor-
mance liquid chromatography and 8-epi-prostaglandin-F2a with
enzyme-linked immunosorbent assay (ELISA). We compared
4 groups: (1) controls (CONTR, N = 14), (2) patients with
chronic kidney disease (CKD, N = 12), (3) patients with type
2 diabetes mellitus (DIAB, N = 17), (4) patients with chronic
kidney disease and type 2 diabetes (DIAB-CKD, N = 19).
Results. We found a decreased plasma para-tyrosine level
and decreased urinary para-tyrosine excretion in CKD patients,
while the fractional excretion of para-tyrosine was similar in
all 4 groups, approximately 1%. There was no difference in the
plasma ortho-tyrosine levels between the groups. However, uri-
nary ortho-tyrosine excretion was higher in all 3 groups of pa-
tients than in the CONTR group, and higher in DIAB and in
DIAB-CKD patients than in CKD patients. The fractional ex-
cretion of ortho-tyrosine was significantly higher in DIAB and
in DIAB-CKD patients than in the CONTR group. The frac-
tional excretion of ortho-tyrosine exceeded 100% in the 2 di-
abetic groups. Urinary 8-epi-prostaglandin-F2a /creatinine ratio
did not correlate with urinary ortho-tyrosine excretion.
Conclusion. The difference between para-tyrosine levels of
the groups is probably due to renal impairment, while there is
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indirect evidence for an increased tubular secretion or produc-
tion of ortho-tyrosine in the kidney in diabetic patients with or
without CKD.
Oxidative stress has been implied for a long time as
a key process in the development of complications of
diabetes mellitus and chronic renal disease [1, 2]. The
imbalance between free radicals and antioxidant sys-
tems gives rise to free radical-mediated damage. Metal-
catalyzed oxidation reactions, like the Fenton reaction,
where hydrogen peroxide is cleaved to hydroxyl free
radical and hydroxyl anion, play an important role in
the generation of oxidative stress [3]. In diabetes mel-
litus there is an increased oxidative stress (e.g., due to
the high glucose concentrations). In chronic renal fail-
ure, there is a microinflammatory state, caused by uremic
toxins, an enhanced formation and a decreased clearance
of proinflammatory cytokines (e.g., TNF-a, IL-12), and
an accumulation of advanced glycation end products [4].
Amino acid oxidation-products are stable and specific
markers of free radical production [5]. Reactive oxy-
gen species such as superoxide and hydroxyl free rad-
icals damage protein-bound or free amino acids [6, 7].
Aromatic side chain amino acids are susceptible to oxida-
tive stress, and their products (e.g., ortho-tyrosine, meta-
tyrosine, and dityrosine) are stable [1].
The essential amino acid phenylalanine (Phe) is con-
verted to the physiologic, semi-essential para-tyrosine (p-
Tyr) by the phenylalanine hydroxylase enzyme. No other
isoform of tyrosine is formed in this enzymatic reaction.
In the presence of hydroxyl free radical Phe can be hy-
droxylated in para, meta, and ortho positions. Thus, para-,
meta-, and ortho-tyrosine (p-, m-, o-Tyr) are all formed
in this free radical-reaction (Fig. 1). Consequently, p-Tyr
may be formed both physiologically and in the oxidative
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Fig. 1. Conversion reactions of phenylalanine (Phe) to para-meta- and
ortho-tyrosine (p-, m-, o-Tyr). The wide (→) arrow represents the en-
zymatic reaction, while the narrow arrow (→) shows the reactions in
the presence of hydroxyl free radical (·OH). Abbreviations are: Phe,
phenylalanine; p-Tyr, para-tyrosine; m-Tyr, meta-tyrosine; o-Tyr, ortho-
tyrosine; ·OH, hydroxyl free radical.
processes, while m- and o-Tyr are selective hydroxyl free
radical markers [7, 8]. o- and m-Tyr have been used as
markers of hydroxyl free radical formation, among oth-
ers, in sera of euthyroid subjects after triiodothyronin
administration [9], in cataractous lenses [10], and in the
plasma after myocardial ischemia-reperfusion [11].
Accumulation of o- and m- Tyr has been widely de-
scribed as correlating with an increase of malondialde-
hyde formation [12], an increase in NADPH oxidase
activity, an increased level of oxidized fatty acids [13],
a decrease in reduced glutathione levels [14], and others.
Oxidized amino acid derivatives are superior to other
oxidative stress markers (e.g., lipid peroxidation prod-
ucts, glycoxidation products) because they are reliable,
specific, highly stable markers, and are not produced in
sample preparation procedures. Moreover, o-Tyr can be
detected well through its autofluorescence [6].
Amino acids are filtered in the glomeruli and reab-
sorbed from the primary filtrate in the renal tubules. The
route of reabsorption depends on the nature and chemical
structure of the amino acid. Both Phe and p-Tyr are re-
absorbed via the transporters of the neutral amino acids.
This process is of high efficacy, with only 1% of the fil-
tered amino acids escaping with the urine [15]. Beside
filtration, there are other sources of urinary amino acids,
such as tubular secretion at the apical membrane and
tubular brush border peptidases that split oligopeptides
to amino acids. The fractional excretion (Fex) of p-Tyr
and Phe varies at around 1% (mean Fex of p-Tyr, 1.18%;
mean Fex of Phe, 0.9%) in humans [15].
The aims of this study were to measure p-, m-, o-Tyr,
and Phe concentrations both in urine and in plasma sam-
ples of controls, of patients with type 2 diabetes mellitus
or chronic kidney disease or a combination of both. We
also investigated the correlation between the levels of
urinary 8-epi-prostaglandin-F2a , a marker of lipid perox-
idation, with the hydroxyl free radical marker, o-Tyr. We
examined the renal handling of the physiologically pro-
duced and the hydroxyl radical-derived Tyr isomers.
METHODS
Patient groups
In a cross-sectional clinical study, 4 groups of patients
were investigated: (1) a group of nondiabetic control sub-
jects without chronic kidney disease (CONTR, N = 14);
(2) a group of patients with stage III chronic kidney dis-
ease (CKD, N = 12); (3) type 2 diabetic patients (DIAB,
N = 17); and (4) patients with type 2 diabetes and stage
III. chronic kidney disease (DIAB-CKD, N = 19). Me-
dians of measured and predicted clearance (Table 1) in
the CKD and DIAB-CKD groups were in the range of
stage III CKD (moderate decrease of GFR) according to
the Definition and Classification of the Stages of Kid-
ney Disease by the National Kidney Foundation (i.e.,
30–59 mL/min). Diagnoses of the patients with chronic
kidney disease were chronic pyelonephritis (N = 4), poly-
cystic kidney disease (N = 3), nephrosclerosis (N = 2),
IgA nephropathy (N = 1), minimal change disease (N =
1), and renal vasculitis (N = 1). The groups did not show
any significant difference in regards to their age (P =
0.426) or gender (P = 0.723).
There was no significant difference between the CKD
and the DIAB-CKD patients regarding the severity of
their renal impairment [serum creatinine, P = 0.795; mea-
sured creatinine clearance, P = 0.272; predicted creati-
nine clearance (Cockroft-Gault), P = 0.820]. The DIAB
and the DIAB-CKD groups did not differ in their fruc-
tosamine (P = 0.797) and hemoglobin A1c levels (P =
0.298). There was no significant difference between the
groups in the parameters of liver function (e.g., serum
ALAT, lactic acid dehydrogenase, and alkaline phos-
phatase activities), serum total cholesterol, HDL and
LDL cholesterol (data not shown). Important clinical
characteristics of the 4 groups are shown in Table 1.
Twenty-four–hour collected urine and heparinized
fasting plasma samples were obtained, and routine clin-
ical parameters were also measured. As diet may influ-
ence plasma o-Tyr levels, fasting plasma samples were
obtained. For determination of laboratory parameters,
standard methods were used. The study was approved by
the Ethical Committee of the Medical Faculty of the Uni-
versity of Pe´cs. All patients and controls gave informed
consent.
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Table 1. Clinical characteristics of the four groups of patients
CONTR CKD DIAB DIAB-CKD
Number of cases 14 12 17 19
Gender male/female 4/10 5/7 7/11 8/12
Age years 61 54 62 69
(54–65) (51–65) (57–69) (59–73)
Blood urea nitrogen mmol/L 4.8 12.3a 7.3b 16.2a,c
(4.1–6.0) (10.2–15.8) (6.5–9.5) (13.1–23.9)
Serum creatinine lmol/L 79 190a,c 81 196a,c
(70–90) (147–255) (68–88) (173–257)
Creatinine clearance
Measured mL/min 109 31a,c 109 38a,c
(83–140) (16–33) (93–124) (23–41)
Predicted (Cockroft) mL/min 80 35a,c 109 38a,c
(71–87) (30–56) (90–144) (25–53)
Fructosamine lmol/L – – 267 259
(243–304) (235–367)
Hemoglobin A1c% – – 8.65 7.13
(8.22–9.59) (6.23–9.01)
Abbreviations are: CONTR, group of healthy control subjects; CKD, group of patients with stage III chronic kidney disease; DIAB, group of diabetic patients;
DIAB-CKD, group of patients with diabetes and stage III chronic kidney disease. Data are shown as median and (interquartile range). The Mann-Whitney U test was
only used when the Kruskal-Wallis test for all groups was significant (P < 0.05).
aP < 0.05 vs. control subjects.
bP < 0.05 vs. CKD patients.
cP < 0.05 vs. type 2 diabetic patients.
Determination of non–protein-bound ortho- and
para-tyrosine in urine and fasting plasma samples
A modification of the method described by Ishimitsu
et al [16] was used for the analysis. Briefly, from the
24-hour collected urine or freshly obtained fasting hep-
arinized plasma samples, aliquots of 250 lL were taken
and handled on ice. One hundred and twenty-five mi-
croliters of 60% trichloroacetic acid was added to the
samples, vortexed, and incubated 30 minutes on ice to
precipitate protein content. To remove the precipitate,
samples were then centrifuged at 15,000 rpm for 10 min-
utes in Eppendorf tubes. The supernatant was filtered
through a 0.2 lm syringe filter (Millipore, Billerica, MA,
USA), and 20 lL was injected into the manual injector
of the high-performance liquid chromatography (HPLC)
device.
The analysis was performed using a Shimadzu Class
LC-10 ADVP HPLC system (Shimadzu USA Manufac-
turing, Inc., Canby, OR, USA) equipped with a Shimadzu
RF-10 AXL fluorescent detector (Shimadzu USA Manu-
facturing, Inc.). The amino acids (p-, m-, o-Tyr, Phe) were
measured upon their autofluorescence, the Tyr isoforms
at 275 nm excitation and 305 nm emission wavelengths,
while Phe at 258 nm excitation and 288 nm emission wave-
lengths. The analysis was performed using a Licrospher
C-18 ODS column, in an isocratic run using an aque-
ous solution of 1% acetic acid and 1% sodium-acetate as
the mobile phase. External standard calibration and mea-
surement of areas under the curve were used to calculate
the exact concentrations of the investigated amino acids.
In some cases, standard peak-addition was also used to
verify the elution time of the substances. p-, m-, Tyr, and
Phe were obtained from Sigma-Aldrich Co. (St. Louis,
MO, USA), while o-Tyr was from ICN Biochemicals, Inc.
(Aurora, OH, USA).
Determination of urinary 8-epi-prostaglandin-F2a
Urinary 8-epi-prostaglandin-F2a levels were deter-
mined by a competitive enzyme-linked immunosorbent
assay (ELISA) assay kit purchased from Oxis Research
(Oxis Health Products, Portland, OR, USA).
Statistical analyses
As most data were of non-normal distribution, we
used the nonparametric Kruskall-Wallis test and Mann-
Whitney U test and Spearman’s rho correlation. Because
of the non-normal distribution, median and interquar-
tile ranges were used to characterize distribution of the
data. To reduce false-positive results, multiple compar-
isons were carried out using Kruskall-Wallis and median-
test, while the Mann-Whitney U test was only used for
2-group comparisons, where P values < 0.05 were re-
garded as statistically significant.
RESULTS
Evaluation of the method
Both o- and p-Tyr could be well detected in the urine
samples (Fig. 2). Urinary Phe levels were below detec-
tion limit in the majority of cases, so urinary Phe lev-
els were not measured. In the plasma samples, p-, o-Tyr,
and Phe were present, all at well measurable concentra-
tions. Lower theoretic limit of detection for o-Tyr has
been calculated, proving to be 7 nmol/L. m-Tyr was ei-
ther not detectable or coeluted with another substance






















Fig. 2. Chromatogram of urine samples of a
patient from the control group (—) and a pa-
tient with diabetes and chronic kidney dis-
ease (– – –). Abbreviations are: p-Tyr, para-
tyrosine; o-Tyr, ortho-tyrosine.
Table 2. Plasma level and urinary excretion para- and ortho-tyrosine
CONTR CKD DIAB DIAB-CKD
Plasma p-Tyr lmol/L 55.96 28.45a,c 46.11 32.46c
(35.62–56.97) (25.60–34.42) (42.09–49.31) (29.15–39.01)
Urine p-Tyr/creatinine lmol/mmol 4.27 1.80a,c 5.31 1.95c
(3.03–5.23) (1.58–1.97) (4.26–9.28) (1.45–3.90)
Urinary p-Tyr excretion lmol/day 23.62 18.78c 68.78 20.44c
(16.79–81.57) (5.10–40.98) (43.84–113.63) (9.11–29.74)
p-Tyr Fex % 0.67 1.36 0.98 1.06
(0.56–0.79) (1.09–2.14) (0.73–1.35) (0.71–3.54)
Plasma o-Tyr lmol/L 0.022 0.050 0.023 0.054
(0.013–0.054) (0.024–0.145) (0.015–0.029) (0.019–0.378)
Urine o-Tyr/creatinine lmol/mmol 0.034 0.175a 0.291a 0.479a,c
(0.0001–0.035) (0.056–0.481) (0.103–0.330) (0.367–0.701)
Urinary o-Tyr excretion lmol/day 0.24 1.22a 3.41a,b 4.03ab
(0.00–0.35) (0.94–1.83) (2.72–4.99) (2.58–6.51)
o-Tyr Fex% 7.86d 27.28 125.29a 111.89a
(3.81–12.08) (8.55–373.02) (69.32–140.35) (68.79–185.90)
Abbreviations are: CONTR, group of healthy control subjects; CKD, group of patients with stage III chronic kidney disease; DIAB, group of diabetic patients;
DIAB-CKD, group of patients with diabetes and stage III chronic kidney disease; p-Tyr, para-tyrosine; o-Tyr, ortho-tyrosine; Fex, fractional excretion. Data are shown
as median (interquartile range). The Mann-Whitney U test was only used when the Kruskal-Wallis test for all groups was significant (P < 0.05).
aP < 0.05 vs. control subjects.
bP < 0.05 vs. CKD patients.
cP < 0.05 vs. type 2 diabetic patients.
dP < 0.05 vs. p-Tyr Fex.
(proven by standard peak-addition); therefore, it was not
determined.
To test the reproducibility of the method, interassay
variations of 9 urine and plasma samples from 3 repeated
measurements were calculated. Between the analyses, the
samples were stored at −20◦C, being frozen and thawed
for each measurement. The tests were performed on 3 dif-
ferent days, using the same equipment, and each time the
whole sample-handling procedure was carried out. The
average interassay CVs in our study were 7.8% for uri-
nary p-Tyr concentration and 7.7% for urinary o-Tyr con-
centration. Averages of CVs were 7.1% for plasma p-Tyr
concentration and 6.3% for plasma o-Tyr concentration.
Median concentration of 8-epi-prostaglandin-F2a in
our study population was 1049 ng/mmol creatinine, which
corresponds to the range described in the literature (10–
1600 ng/mmol creatinine in an analysis of the Framing-
ham study group) [17].
Plasma levels and urinary excretion of para-tyrosine
We found that the CKD group had a significantly lower
plasma level of p-Tyr than the CONTR and the DIAB
groups. Also, the DIAB-CKD group had a lower plasma
p-Tyr level than the DIAB group (Table 2). We ob-
tained similar results when correcting data to the plasma
Phe levels (data not shown). Phe levels did not differ
among the patient groups (median plasma Phe levels
were 40.50 lmol/L for the CONTR group, 27.52 lmol/L
for the CKD group, 31.08 lmol/L for the DIAB group,
30.03 lmol/L for the DIAB-CKD group, P = 0.448).
Urinary levels of p-Tyr were corrected for urinary con-
centrations of creatinine. Urinary concentrations of cre-
atinine did not differ in the groups (data not shown). The
CONTR group had a higher urinary p-Tyr/creatinine ra-
tio than the CKD group. Also, the DIAB group had a
higher p-Tyr/creatinine value than the CKD or the DIAB-
CKD groups (Table 2). When daily p-Tyr excretion was
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calculated, we found that the CKD and the DIAB-CKD
groups had a lower p-Tyr excretion than the DIAB group
(Table 2). Plasma levels of p-Tyr correlated with urinary
levels of p-Tyr (r = 0.468, P = 0.001).
Renal clearance and fractional excretion of para-tyrosine
The CKD and the DIAB-CKD group had a lower p-
Tyr clearance than the DIAB group [0.34 (0.12–0.64) and
0.46 (0.18–0.74) vs. 1.13 (0.58–1.64) mL/min, P < 0.05].
We found no difference when comparing the patient
groups with the CONTR group [CONTR, 0.63 (0.26–
0.99) mL/min]. To check the effect of the renal impair-
ment on the handling of p-Tyr, fractional excretion (Fex)
was calculated. There was no difference between the
groups with regard to the Fex of p-Tyr (Table 2).
Plasma levels and urinary excretion of ortho-tyrosine
The CKD and the DIAB-CKD groups tended to have
a higher plasma o-Tyr level than the CONTR group, but
the observed difference was not significant (P = 0.286,
Table 2). We obtained similar results when correcting
data to the serum Phe levels (data not shown).
The urinary o-Tyr/creatinine ratio was higher in the 3
groups of patients than in the CONTR group, and higher
in the DIAB-CKD group than in the DIAB group. The
3 groups of patients had significantly higher daily o-Tyr
excretion than the CONTR group. The daily o-Tyr excre-
tion of the 2 diabetic groups was also higher than in the
CKD group (Table 2). The correlation between plasma
levels of o-Tyr and urinary levels of o-Tyr was not signif-
icant (r = 0.219, P = 0.130).
Urinary 8-epi-prostaglandin-F2a /creatinine ratio did
not correlate with plasma o-Tyr (r = 0.04), plasma o-
Tyr/Phe ratio (r = −0.06), urinary o-Tyr/creatinine ratio
(r = 0.12), or urinary o-Tyr excretion (r = 0.16, P > 0.05
for all).
Renal clearance and fractional excretion
of ortho-tyrosine
There was no significant difference in the o-Tyr clear-
ance among the groups [CONTR, 12.21 (2.13–21.26);
CKD, 5.92 (2.64–59.68); DIAB, 122.34 (47.01–204.86);
DIAB-CKD, 29.14 (8.94–76.22) mL/min, P = 0.070].
In the case of o-Tyr we found that the DIAB and the
DIAB-CKD groups had a significantly higher Fex of o-
Tyr than the CONTR group. The median Fex of o-Tyr
exceeded 100% in both diabetic groups (Table 2). The
Fex of o-Tyr was significantly higher than the Fex of p-
Tyr in the control group (Table 2).
Urinary 8-epi-prostaglandin-F2a /creatinine ratio did
not correlate with o-Tyr clearance or Fex of o-Tyr (r =
0.01 and r = −0.167, respectively; P > 0.05 for all).
DISCUSSION
In a cross-sectional study, we determined urinary and
plasma p- and o-Tyr levels in diabetes and renal failure.
We proved that our method was suitable for the mea-
surement of both urinary and plasma non–protein-bound
p- and o-Tyr with a good reproducibility. The plasma p-
Tyr, o-Tyr, and Phe levels corresponded with the range
described in the literature. Using this method, Ishimitsu
et al found mean p-, o-Tyr, and Phe serum concentrations
of 52 lmol/L, 17 nmol/L, and 58 lmol/L in healthy per-
sons [16], while medians of our results for the CONTR
group were 56 lmol/L (p-Tyr), 22 nmol/L (o-Tyr), and
40 lmol/L (Phe), respectively.
From data of an animal experiment [18] we know that
serum levels of free o-Tyr reach highest concentrations
at 15 minutes after oral, intramuscular or intraperitoneal
Phe administration. Therefore, changes of free o-Tyr lev-
els might be indicative of short-term free radical pro-
cesses. However, the turnover of protein-bound o-Tyr
is slower than that of free o-Tyr, and so we also tried
to detect m- and o-Tyr in plasma protein hydrolysates.
We found that m- and o-Tyr in the plasma protein hy-
drolysates did not resolve well from other peaks; there-
fore, they could not be measured using our method.
According to the literature, the concentration of non–
protein-bound free o-Tyr is 4.03 times higher than the
concentration of protein-bound o-Tyr in the plasma [19].
A major aim of this study was to obtain information on
the renal handling of p-Tyr and o-Tyr. To be able to calcu-
late renal clearance and Fex of the substances, we needed
to measure the non–protein-bound form of p-Tyr and
o-Tyr.
It is known that in uremia there is an impaired amino
acid metabolism [20, 21]. Through the amino acid analysis
of uremic and azotemic sera, lower p-Tyr concentrations
were found than in healthy controls (CKD vs. controls:
26 vs. 46 lmol/L [22], and 27 vs. 54 lmol/L [23]). Our
corresponding data were 28 versus 56 lmol/L. The latest
data of the literature imply that renal impairment causes
a decreased renal phenylalanine-hydroxylase enzyme ac-
tivity [24]. In our case, the p-Tyr Fex values were all below
100% (range for all groups 0.24–20.67%), indicating that
p-Tyr is effectively retained by the kidney. A decreased
synthesis of p-Tyr is indicated by the fact that patients
with CKD had decreased plasma p-Tyr levels with a Fex
similar to the CONTR group.
Free radical–derived damage has been suspected to
have a biologically relevant role in the pathogenesis of
complications of diabetes or chronic uremia [25]. Thus,
identification of well detectable and stable markers of ox-
idative damage is of special interest. Among the oxidative
stress markers, F2-isoprostanes are specific to lipid per-
oxidation processes, and they are also generated during
sample storage and handling [5]. On the contrary, o-Tyr
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is specific for the hydroxyl free radical–derived damage
of Phe. The fact that the 8-epi-prostaglandin-F2a /crea-
tinine ratio did not correlate with the parameters of o-
Tyr excretion is probably due to the different origin of
8-epi-prostaglandin-F2a and o-Tyr. Today, m-, o-Tyr, and
dityrosine are accepted specific markers of hydroxyl free
radical [26–28]. In our study, we observed an additive ef-
fect of diabetes and kidney failure on the excretion of the
hydroxyl radical marker o-Tyr.
The abundance of plasma Phe (27.52 lmol/L Phe vs.
0.05 lmol/L o-Tyr in the CKD group) makes it unlikely
that the amount of Phe would be rate-limiting in the o-
Tyr formation. Plasma o-Tyr/Phe ratio and plasma o-Tyr
concentration showed the same tendencies. This also sup-
ports that o-Tyr levels would rather reflect hydroxyl rad-
ical formation than the changes in Phe levels.
The lack of correlation between urinary excretion and
plasma level of o-Tyr may indicate that the urinary excre-
tion of o-Tyr is not determined by glomerular filtration
alone, but by active renal transport processes, as well.
Our data also confirm that the renal handling of o-Tyr is
different among the patient groups. The median of frac-
tional excretion of o-Tyr was above 100% in both dia-
betic groups. Such a Fex value of a substance could be
a consequence of 2 processes (i.e., active tubular secre-
tion of the substance or production of the substance in
loco in the kidney). With our data, we cannot distinguish
which process is superior. In diabetes, concentration of
glucose in the urine may rise from 100 to 200 mmol/L
(unpublished data). Glucose-derived oxidative stress on
tubular cells may increase the production and, in this
way, Fex of o-Tyr in the DIAB and the DIAB-CKD
groups.
Our data also suggest that p-Tyr is more efficiently (ap-
proximately 10 times) retained by the kidney than o-Tyr,
even in the control group (Table 2), which indicates a dif-
ferent renal handling of p- and o-Tyr even though the only
difference between the 2 amino acids is the location of the
hydroxyl group. This may be an adaptive process, as the
physiologic Tyr isoform is retained, while the pathologic
isoform is excreted.
CONCLUSION
We found that the physiologic p-Tyr is retained by both
the healthy and the damaged kidney. Also, its production
is decreased in renal impairment. According to our find-
ings and data of the literature, measurement of urinary
and plasma o-Tyr is a simple and valuable method for the
indirect detection of hydroxyl free radical production. In
patients with type 2 diabetes mellitus with or without re-
nal failure, the renal excretion of o-Tyr is enhanced as a
consequence of an increased renal tubular secretion or
production.
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